Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update

• Published in: Stroke (1970) 2017-04, Vol.48 (4), p.867-872
• Main Authors: Hart, Robert G, Catanese, Luciana, Perera, Kanjana S, Ntaios, George, Connolly, Stuart J
• Format: Article
• Language: English
• Subjects: Adult; Aged; Anticoagulants - therapeutic use; Brain Ischemia - drug therapy; Brain Ischemia - epidemiology; Brain Ischemia - etiology; Female; Humans; Intracranial Embolism - complications; Intracranial Embolism - drug therapy; Intracranial Embolism - epidemiology; Male; Middle Aged; Stroke - drug therapy; Stroke - epidemiology; Stroke - etiology
• ISSN: 0039-2499; 1524-4628
• DOI: 10.1161/STROKEAHA.116.016414

BACKGROUND AND PURPOSE—Embolic stroke of undetermined source (ESUS) designates patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke mechanism. It has been hypothesized that anticoagulation is more efficacious than antiplatelet therapy for secondary stroke prevention in ESUS patients. We review available information about ESUS. METHODS—Systematic literature review to assess the frequency of ESUS, patient features, and prognosis using PubMed from 2014 to present, unrestricted by language. RESULTS—On the basis of 9 studies, the reported frequency of ESUS ranged from 9% to 25% of ischemic strokes, averaging 17%. From 8 studies involving 2045 ESUS patients, the mean age was 65 years and 42% were women; the mean NIH stroke score was 5 at stroke onset (4 studies, 1772 ESUS patients). Most (86%) ESUS patients were treated with antiplatelet therapy during follow-up, with the annualized recurrent stroke rate averaging 4.5% per year during a mean follow-up of 2.7 years (5 studies, 1605 ESUS patients). CONCLUSIONS—ESUS comprises about 1 ischemic stroke in 6. Patients with ischemic stroke meeting criteria for ESUS were relatively young compared with other ischemic stroke subtypes and had, on average, minor strokes, consistent with small emboli. Retrospective methods of available studies limit confidence in stroke recurrence rates but support a substantial (>4% per year) rate of stroke recurrence during (mostly) antiplatelet therapy. There is an important need to define better antithrombotic prophylaxis for this frequently occurring subtype of ischemic stroke.